Kamat - Figure 20

64% of ‘failures’ salvaged with additional 3 weeks of BCG

References

[14]

Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124−9  http://dx.doi.org/10.1016/S0022-5347(05)67707-5